Response after peripheral blood stem cell transplantation (PBSCT) (median follow-up 10.8 months).*
| . | N . | Response, % . | Stable, % . | Not Evaluated, % . |
|---|---|---|---|---|
| * 1 died before evaluation and 1 too soon to evaluate | ||||
| † One patient showed borderline worsening at 15 months, but at 24 months, patient reported substantial improvement; no repeat neuropathy impairment score was performed. | ||||
| ‡ 2 complete responses, 3 very good partial response, and 1 minimal response | ||||
| This research was originally published in Blood. Dispenzieri et al. POEMS Syndrome: Definitions and Long-term Outcome. . © by the American Society of Hematology. Blood . 2003 ;101 :2496 –2506 | ||||
| Neurologic | 16 | 87 | … | 13 |
| Subjective | 16 | 87 | … | 13 |
| Nerve conduction studies (at 1 yr) | 11 | 36 | 9 | 55 |
| Neuropathy impairment score | 16† | 25 | 12 | 56 |
| Hematologic | 16 | 56 | 6 | 37 |
| Non-secretory | 3 | NA | NA | 100 |
| Immunofixation only | 7 | 43 | 14 | 43 |
| Serum protein electrophoresis (SPEP) evaluable | 6 | 100‡ | … | … |
| Organ | 11 | 82 | … | 18 |
| Hepatomegaly | 5 | 60 | … | 40 |
| Splenomegaly | 10 | 50 | 20 | 30 |
| Lymphadenopathy | 7 | 71 | 29 | 0 |
| Extravascular volume overload | 14 | 79 | … | 21 |
| Ascites | 6 | 83 | … | 17 |
| Effusion | 4 | 100 | … | … |
| Edema | 14 | 79 | … | 21 |
| Skin changes | 13 | 54 | 15 | 31 |
| Papilledema | 4 | 50 | … | 50 |
| Endocrine | 13 | 23 | 8 | 69 |
| Pulmonary | 15 | 20 | … | 80 |
| . | N . | Response, % . | Stable, % . | Not Evaluated, % . |
|---|---|---|---|---|
| * 1 died before evaluation and 1 too soon to evaluate | ||||
| † One patient showed borderline worsening at 15 months, but at 24 months, patient reported substantial improvement; no repeat neuropathy impairment score was performed. | ||||
| ‡ 2 complete responses, 3 very good partial response, and 1 minimal response | ||||
| This research was originally published in Blood. Dispenzieri et al. POEMS Syndrome: Definitions and Long-term Outcome. . © by the American Society of Hematology. Blood . 2003 ;101 :2496 –2506 | ||||
| Neurologic | 16 | 87 | … | 13 |
| Subjective | 16 | 87 | … | 13 |
| Nerve conduction studies (at 1 yr) | 11 | 36 | 9 | 55 |
| Neuropathy impairment score | 16† | 25 | 12 | 56 |
| Hematologic | 16 | 56 | 6 | 37 |
| Non-secretory | 3 | NA | NA | 100 |
| Immunofixation only | 7 | 43 | 14 | 43 |
| Serum protein electrophoresis (SPEP) evaluable | 6 | 100‡ | … | … |
| Organ | 11 | 82 | … | 18 |
| Hepatomegaly | 5 | 60 | … | 40 |
| Splenomegaly | 10 | 50 | 20 | 30 |
| Lymphadenopathy | 7 | 71 | 29 | 0 |
| Extravascular volume overload | 14 | 79 | … | 21 |
| Ascites | 6 | 83 | … | 17 |
| Effusion | 4 | 100 | … | … |
| Edema | 14 | 79 | … | 21 |
| Skin changes | 13 | 54 | 15 | 31 |
| Papilledema | 4 | 50 | … | 50 |
| Endocrine | 13 | 23 | 8 | 69 |
| Pulmonary | 15 | 20 | … | 80 |